(Toronto, Ontario) – Helix BioPharma Corp. - TheNewswire - (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, announces the filing of the Company's unaudited interim financial statements as of and for the nine month period ended April 30, 2025 (the “Financial Statements” ), the management's discussion and analysis ( “MD&A” ), and the certifications of the Chief Executive Officer and Chief Financial Officer (respectively, “CEO” and “CFO” ) relating to the Financial Statements (collectively, the “Interim Filings” ). The Interim Filings are available on the Company's profile at www.sedarplus.ca .     About Helix BioPharma

Mon, Jun. 16, 2025

2 June 2025 – TheNewswire - (Toronto, Ontario) – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, today announced that the Company has appointed Rohit Babbar, CPA as Chief Financial Officer ( “CFO” ) of the Company, replacing James B. Murphy, CPA as Fractional CFO.   Rohit Babbar is Certified Public Accountant with fourteen years of experience leading accounting operations and financial strategy across fast-growing private and publicly listed small to mid-sized companies in Canada and the US. He is a Director at Brio Financial Group ( “Brio” ), a financial consulting firm that provides outsourced CFO services, financial planning and analysis, and strategic advisory support to emerging growth companies. Over the course of his career, Mr. Babbar has delivered impact across strategic growth and operational efficiency, leading transformative initiatives such as a USD 50 million private equity deal that helped drive a tenfold revenue increase from USD 20 million to USD 200 million. Mr. Babar will be supported by an experienced team of professionals from Brio specializing in accounting and finance, capital raising and administrative operations, as Helix enters a new phase of growth that includes plans to relocate to the US, pursue a NASDAQ listing, and close a substantial equity financing to support upcoming clinical studies.

Mon, Jun. 02, 2025

May 20 , 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, is pleased to announce that the Company has closed the acquisitions of the assets of Laevoroc Immunology AG (“ Laevoroc Immunology ”) and Laevoroc Chemotherapy AG (“ Laevoroc Chemotherapy ”), pursuant to the asset purchase agreements dated November 28, 2024, and November 30, 2024, respectively, as amended (the “ Agreements ”).   Acquisition of LEUMUNA™ and GEMCEDA

Tue, May. 20, 2025

May 14, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, announced today that it has signed an agreement with Kerentech Consulting Ltd. ( “Kerentech” ), under which Kerentech will support Helix in its ongoing fundraising efforts.   Under the terms of the agreement, Kerentech will assist Helix in closing a bridge financing round of USD 13 million to advance the company's lead therapeutic programs and strategic priorities through 2025 and beyond. The collaboration reflects Helix's commitment to accelerating efforts to secure a stable financial platform and fast-track the development of its pipeline candidates this year, beginning with its lead candidate, Tumor Defense Breaker™ L-DOS47.

Wed, May. 14, 2025

April 10, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, today announced the appointment of Thomas Mehrling, MD, PhD as Chief Executive Officer ( “CEO” ) of the Company. A sharpening of Helix's leadership structure, outgoing CEO, Jacek Antas , will dedicate his focus to his role as Chairman of the Company, and Dr. Mehrling, who has shaped Helix's clinical strategy in his capacity as Chief Medical Officer ( “CMO” ), takes the helm to deliver on the Company's ambitious clinical milestones planned for 2025 and beyond.   A distinguished Hemato-Oncologist and Pharmacologist with over 20 years of experience in pharmaceutical oncology, Dr. Mehrling has a proven track record of building successful, global oncology businesses and delivering transformative therapies to the market. As a key architect of Mundipharma International Ltd.'s European oncology business, Dr. Mehrling served as Head of Business Development (2000–2004), European Director of Oncology (2004-2011), and International Director of Oncology Strategy (2011-2013), introducing groundbreaking cancer drugs across Europe that achieved sales nearing USD 1 billion (DepoCyte® and Levact®, Ribomustin® and Treanda®). In 2013, he led the establishment and took the helm of Mundipharma EDO GmbH, a Swiss-based start-up within the Mundipharma Group dedicated to the development of highly selective inhibitors and targeted medicines for hematological malignancies and solid tumors. In 2019, he founded Laevoroc Medical AG, a privately held, Swiss oncology company, whose asset acquisition by Helix laid the foundations for a broader strategic collaboration between Dr. Mehrling and the Company. Prior to his tenure at Mundipharma, Dr. Mehrling served as Senior Vice President of global CRO Medical Affairs at Staticon International, and as Medical Leader at Takeda European R&D Center. Before his transition to the pharmaceutical industry, Dr. Mehrling spent 13 years as an MD at the University Hospital in Frankfurt, where he earned his MD degree from the Department of Internal Medicine (Hemato-oncology and Cardiology) and his PhD in Pharmacology.

Thu, Apr. 10, 2025